Company intelligence / Profile preview

Bavarian Nordic

Ownership: Public · BAVA
Employees: ~1379
Development stage: Commercial

Overview

Bavarian Nordic has successfully commercialized multiple vaccines for infectious diseases including smallpox/monkeypox (Jynneos/Imvanex/Imvamune), rabies (Rabipur/RabAvert), tick-borne encephalitis (Encepur), cholera (Vaxchora), and typhoid fever (Vivotif). In early/mid–2025 the company received regulatory approvals in both the US and Europe for Vimkunya™, the world’s first chikungunya vaccine for individuals aged ≥12 years. The company discontinued its immuno-oncology program to focus exclusively on infectious disease vaccines. Its mpox vaccine Jynneos demonstrated robust antibody responses in adolescents comparable to adults; a one-fifth dose was also shown to be effective[4]. The RSV program was discontinued after not meeting endpoints[4].

Therapeutic areas: Infectious Diseases
Modalities: Viral vectors (e.g., MVA-BN platform)Virus-like particles (VLPs)Recombinant vaccines
Industry: Biotech

Drug pipeline

44 assets

vaccinia virus smallpox vaccine

Approved

43 more assets in the full pipeline.

Request access →

Partnerships

Biological E. Limited partnership for chikungunya access in low-/middle-income countries[3]Government contracts with US and European agencies for smallpox/mpox preparedness[6]

Financials

Market cap: $19.8M
Enterprise value: $19.8M

Beyond the preview

Go deeper on Bavarian Nordic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bavarian Nordic.

Explore the full profile